Patel Kinnari

Average Profitability
84.02%
Insider Buys Quantity
2
Insider Buys Sum
$104,011.50
Insider Sells Quantity
8
Insider Sells Sum
$2.46M

Insider Activity of Patel Kinnari

According to the SEC Form 4 filings, Patel Kinnari, being in a position of

  1. See Remarks at Rocket Pharmaceuticals, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 18701 share for $292,484,
    over all time since 2018-12-06, has bought 7675 shares for $104,012, and sold 62219 shares for $2.46M.

The largest purchase of all time was on 2018-12-06 and amounted to 5675 shares of Rocket Pharmaceuticals, Inc. for $85,012.

The largest sale of all time was on 2020-12-28 and amounted to 33522 shares of Rocket Pharmaceuticals, Inc. for $1.9M.

Biography of Patel Kinnari

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
$000
Sells
$292,4844100

Comparison of Insiders on Amount of Buys and Sells

2025-02-21SaleRocket Pharmaceuticals, Inc.
RCKT
See Remarks
6,078
0.0056%
$10.58$64,305-17.39%
2024-11-21SaleRocket Pharmaceuticals, Inc.
RCKT
See Remarks
4,588
0.005%
$13.05$59,892-14.7%
2024-08-16SaleRocket Pharmaceuticals, Inc.
RCKT
See Remarks
3,989
0.0043%
$18.50$73,812-27.52%
2024-05-16SaleRocket Pharmaceuticals, Inc.
RCKT
See Remarks
4,046
0.0045%
$23.35$94,474-26.28%
2024-02-16SaleRocket Pharmaceuticals, Inc.
RCKT
See Remarks
7,132
0.0079%
$29.84$212,805-34.52%
2023-08-17SaleRocket Pharmaceuticals, Inc.
RCKT
See Remarks
1,534
0.0019%
$15.47$23,733+49.9%
2023-05-17SaleRocket Pharmaceuticals, Inc.
RCKT
See Remarks
1,330
0.0017%
$21.38$28,429+4.85%
2020-12-28SaleRocket Pharmaceuticals, Inc.
RCKT
Chief Operating Officer
33,522
0.061%
$56.72$1.9M-25.28%
2020-03-18PurchaseRocket Pharmaceuticals, Inc.
RCKT
Chief Operating Officer
2,000
0.0036%
$9.50$19,000+168.69%
2018-12-06PurchaseRocket Pharmaceuticals, Inc.
RCKT
Chief Operating Officer
5,675
0.0143%
$14.98$85,012-0.66%
Total: 10
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.